ArticleWorld journal of clinical oncology2025
Nomogram for overall survival in ampullary adenocarcinoma using the surveillance, epidemiology, and end results database and external validation.
Article in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmpullary adenocarcinoma is a rare malignant tumor of the gastrointestinal tract. Currently, only a few cases have been reported, resulting in limited information on survival.
aimTo develop a dynamic nomogram using internal and external validation to predict survival in patients with ampullary adenocarcinoma.
methodsData were sourced from the surveillance, epidemiology, and end results stat database. The patients in the database were randomized in a 7:3 ratio into training and validation groups. Using Cox regression univariate and multivariate analyses in the training group, we identified independent risk factors for overall survival and cancer-specific survival to develop the nomogram. The nomogram was validated with a cohort of patients from the First Affiliated Hospital of the Army Medical University.
resultsFor overall and cancer-specific survival, 12 (sex, age, race, lymph node ratio, tumor size, chemotherapy, surgical modality, T stage, tumor differentiation, brain metastasis, lung metastasis, and extension) and 6 (age; surveillance, epidemiology, and end results stage; lymph node ratio; chemotherapy; surgical modality; and tumor differentiation) independent risk factors, respectively, were incorporated into the nomogram. The area under the curve values at 1, 3, and 5 years, respectively, were 0.807, 0.842, and 0.826 for overall survival and 0.816, 0.835, and 0.841 for cancer-specific survival. The internal and external validation cohorts indicated good consistency of the nomogram.
conclusionThe dynamic nomogram offers robust predictive efficacy for the overall and cancer-specific survival of ampullary adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.